The Global Health Body Sounds Alert Over Severe Shortage of Obesity Medications
Fewer than a tenth of patients eligible to benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it releases its initial guidance on the therapies.
Considering over a billion people worldwide currently obese, it is calling for more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key obstacles to broad access to the injections that can help people shift significant weight, says the organization.
Skinny Jab Supply Crisis
Even in the current most favorable case, the production of these medications would only suffice for around 100 million people – fewer than 10% of the global need, according to the health organization.
The recommendation calls on nations and manufacturers to widen access, by strategies including licensing agreements.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Work
These medications imitate a biological compound to delay gastric emptying, reduce hunger and increase satiety so people eat less.
People commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Studies indicates people may regain a significant portion within a year of discontinuing the medication, as their typical food cravings return.
Being overweight or obese elevates your chance for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
